Advertisement
Research Article Free access | 10.1172/JCI112780
Find articles by Chou, C. in: JCI | PubMed | Google Scholar
Find articles by Ho, L. in: JCI | PubMed | Google Scholar
Find articles by Ting, L. in: JCI | PubMed | Google Scholar
Find articles by Hu, C. in: JCI | PubMed | Google Scholar
Find articles by Su, T. in: JCI | PubMed | Google Scholar
Find articles by Chang, W. in: JCI | PubMed | Google Scholar
Find articles by Suen, C. in: JCI | PubMed | Google Scholar
Find articles by Huang, M. in: JCI | PubMed | Google Scholar
Find articles by Chang, C. in: JCI | PubMed | Google Scholar
Published January 1, 1987 - More info
The effects of somatostatin (SRIF), insulin, and triiodothyronine (T3) on the growth of human hepatoma cells were investigated on the well-differentiated human hepatoma cell line Hep3B. Results showed that both insulin and T3 can stimulate cell growth of serum starved Hep3B cells at physiological concentrations. SRIF alone showed little growth-promoting activity. When added concurrently with insulin, however, SRIF suppressed the insulin-induced cell proliferation in a dose-dependent manner. On the other hand, SRIF had no inhibitory effect on T3-induced cell proliferation. SRIF is labile in the medium, with a half-life of about 2 h during culture incubation. SRIF did not disturb the insulin binding to its surface receptors nor inhibit the insulin-dependent receptor kinase activity of Hep3B cells in vitro. These results suggest that postreceptor regulation may be involved. The selective suppression by SRIF of insulin-induced cell growth provides an unique approach to the study of insulin actions on proliferation of human hepatoma cells.
Images.
Click on an image below to see the page. View PDF of the complete article